

THE IMPACT OF ATRIAL FIBRILLATION

AN ESTIMATED **2.7 MILLION** PEOPLE IN THE U.S. HAVE AF.³



WORLDWIDE, AN ESTIMATED **8.8 MILLION ADULTS** OVER 55 YEARS OF AGE HAD AF IN 2010. This number is projected to double by 2060 to 17.6 million.²



PATIENTS WITH AF ARE **5X MORE LIKELY** TO HAVE A STROKE.⁵



MORE THAN **15% OF STROKES** OCCUR IN PATIENTS WITH AF.⁴


AN ESTIMATED **1.5% – 2%** OF THE WORLD'S POPULATION HAS AF, and the average age of people with AF is 75 – 85.¹



CVD ACCOUNTS FOR **17%** OF U.S. DOMESTIC HEALTH EXPENDITURES.⁶



46.1 MILLION PEOPLE WORLDWIDE (0.5% OF THE WORLD'S POPULATION) HAVE AF.¹⁰



5% OF THE U.S. POPULATION CONSUMES 50% OF ALL HEALTH CARE EXPENDITURES.⁷



THE INCIDENCE OF AF HAS INCREASED BY **13% IN THE LAST TWO DECADES**, AND UP TO **16 MILLION AMERICANS** WILL DEVELOP AF BY 2050.⁹



IN 2010, THE GLOBAL PREVALENCE RATE OF AF FOR WOMEN WAS **373 OF 100,000**, A **3.6% INCREASE** SINCE 1990.¹⁰



IN 2010, THE GLOBAL PREVALENCE RATE OF AF FOR MEN WAS **596 OF 100,000**, A **4.6% INCREASE** SINCE 1990.¹⁰



IN 2006, THE DIRECT COST OF AF TREATMENT IN THE U.S. WAS ESTIMATED AT **\$6.65 BILLION**.⁸



BY 2030, THE MEDICAL COSTS FOR CVD WILL TRIPLE FROM **\$273 BILLION TO \$818 BILLION**.⁶



ST. JUDE MEDICAL™

1. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Europace*. 2012;14:1385-1413. doi:10.1093/europace/eus305
2. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. *European Heart Journal*. 2013;34:2746–2751. doi:10.1093/eurheartj/ehs280
3. CDC Atrial Fibrillation Fact Sheet
4. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation*. 2006;114(2):119-125.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor of stroke: the Farmington Study. *Stroke*. 1991;22:983-8.
6. Sullivan E. Health Services Utilization and Medical Costs Among Medicare Atrial Fibrillation Patients. Avalere Health. 2010;4:1-58. http://www.avalerehealth.net/research/docs/Avalere-AFIB_Report-09212010.pdf. Accessed March 15, 2012.
7. Stanton MW. The High Concentration of U.S. Health Care Expenditures: Research in Action, Issue 19. June 2006. Agency for Healthcare Research and Quality, Rockville, MD. <http://www.ahrq.gov/research/findings/factsheets/costs/expriach/index.html>. Accessed March 15, 2012.
8. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. *Value in Health*. 2006;9(5):348–356.
9. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation*. 2006;114(2):119-125.
10. Chugh SS, Havmoeller R, Narayanan K, et al.; Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. *Circulation*. 2014 Feb 25;129(8):837-47.

Unless otherwise noted, TM indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL and the nine-squares symbol are trademarks and service marks of St. Jude Medical, Inc. and its related companies. © 2014 St. Jude Medical, Inc. All Rights Reserved.